Abstract: Immunological checkpoint inhibitors of antiprogrammed cell death-1  and programmed cell death ligand-1 (PD-L1) have already demonstrated remarkable clinical efficacy for solid tumors, however, the effectiveness of single drug therapy in immunotherapy is not very high. Therefore, exploring the appropriate therapeutic predictive biomarkers so as to accurately identify the potential patients suitable for this therapy has become a research hotspot. Studies have shown that biomarkers such as PD-L1, tumor mutation burden and mismatch repair deficiency may be related to the efficacy of immunotherapy. Indepth analysis and exploration of these markers may provide a basis for determining those patients who are more likely to benefit from checkpoint inhibitor.

Key words: Immunotherapy, Biological markers, PD-1, PD-L1